Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06660498 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pomalidomide as an Immune-enhancing Agent for the Control of HIV

Study acronym: PEACH
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Mar 31, 2026 to Mar 31, 2027
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 20, 2024 to May 13, 2025
    • Eligibility criteria shortened, about 27 words
    • Site details revised at 2 of 2 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate the safety and efficacy of pomalidomide in HIV-1-infected individuals on ART and to determine the impact of pomalidomide on virological control in people living with HIV during an analytical treatment interruption.
Trial Details
NCT Number NCT06660498
Lead Sponsor University of Aarhus
Conditions
(from sponsor)		 HIV-1 Infection
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov